Pfizer (PFE) earns a BUY rating with a $32.36 price target, 15% upside, and a 6.19% dividend yield anchoring the rebound thesis.
Pfizer trades at 10x forward earnings, a steep discount to Merck (MRK) at 18x and Bristol Myers Squibb (BMY) at 11x.
CEO Albert Bourla beat consensus revenue nine of ten quarters, with 19 pivotal study starts planned across oncology, obesity, and immunology.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today.
Our 24/7 Wall St. price target for Pfizer (NYSE:PFE) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07. Our recommendation is buy, with high model confidence of 90%. Pipeline momentum, a re-rated 2026 guide, and a 6.19% dividend yield tip the scale toward a rebound thesis.
#target #upside #thesis
Pfizer trades at 10x forward earnings, a steep discount to Merck (MRK) at 18x and Bristol Myers Squibb (BMY) at 11x.
CEO Albert Bourla beat consensus revenue nine of ten quarters, with 19 pivotal study starts planned across oncology, obesity, and immunology.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today.
Our 24/7 Wall St. price target for Pfizer (NYSE:PFE) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07. Our recommendation is buy, with high model confidence of 90%. Pipeline momentum, a re-rated 2026 guide, and a 6.19% dividend yield tip the scale toward a rebound thesis.
#target #upside #thesis
1 day ago
